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The fibroadenoma is the most common benign tumour of the female breast and can 
occur in all age groups with a peak in the third decade. The pathological features of 
fibroadenomas are well known and have recently been reviewed by Fechner (1987). 
The typical fibroadenoma is characteristically well circumscribed, firm and spherical. 
Cut surface is white, glistening and sometimes slightly myxoid. Clefts are often 
discernible and light brown areas indicate the epithelial component. 
As the name implies, the fibroadenoma is composed of fibrous and epithelial 
elements. Microscopically, stromal fibrous tissue comprises the major component. 
The quality of the stroma can be variable, either in the same lesion, or from lesion 
to lesion. It is sometimes loose and myxoid with stellate cells, or it may be quite 
cellular with frequent mitoses and a degree of cellular pleomorphism. The stroma 
can also be sparsely cellular with areas of hyalinised collagen. The stroma can 
compress ducts to slit-like spaces ( the so-called intracanalicular pattern) or the ducts 
may retain their patency with circumferential stroma (the pericanalicular pattern). 
Rarely, the stroma may contain other elements such as mature adipose tissue, 
smooth muscle or metaplastic bone. 
The epithelium is frequently arranged into lobules and numerous extralobular ducts 
which have a double layer of epithelium and myoepithelium, a feature easily 
appreciated with the pericanalicular pattern. With the intracanalicular pattern the 
epithelium is often stretched and thinned and the myoepithelial layer may be lost. 
The epithelium may become stratified sometimes forming papillary excrescences six 
or seven cells thick. Tangential sectioning of these areas may produce complex and 
worrisome patterns, but without cellular atypia. The epithelium and stroma may 
show fibrocystic change, sclerosing adenosis and apocrine metaplasia as is seen in 
benign breast disease. Secretory change, too, may be seen in pregnant or lactating 
women and also occasionally in the non pregnant or lactating state. 
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Although imprecisely understood, fibroadenomas may have a natural history with 
phases of proliferation, involution and even ultimate regression. Furnival et al 
(1983), Kern and Clark (1973) and Foster et al (1988) demonstrated declining 
stromal cellularity with age and many fibroadenomas in the post menopausal period 
are calcified and hyalinised in keeping with an advanced stage of involution. 
However, some have appeared histologically as cellular and active as tumours of 
younger women (Fechner, 1987). 
It has been estimated that fibroadenomas take 6-12 months to double in size, growth 
usually ceasing when a 2 or 3 cm diameter is reached (Haagensen, 1971). In a small 
group of patients the tumours may reach very large sizes of between 12-15 cm and 
are termed giant fibroadenomas. Most, but not all, giant fibroadenomas occur in 
adolescence and grow rapidly to attain a size two to four times the size of the 
opposite breast with stretching of the overlying skin and displacement of the nipple. 
Morphologic changes in fibroadenomas in relation to phase of the menstrual cycle 
have not been investigated. Such changes have, however, been described in normal 
breast tissue and it is possible that similar changes may occur in fibroadenomas. In 
the normal breast, with progression of the cycle, increasing acinar cell 
differentiation, acinar lurninal diameter, myoepithelial cell vacuolisation, active 
secretion, stromal oedema and stromal lymphocytic infiltrate have been described 
(Vogel et al 1981, Longacre and Bartow, 1986). 
Studies on normal breast have also shown changes in cell proliferation with the 
menstrual cycle with a peak in the second half of the cycle. Cell proliferation has 
also been shown to decline significantly with age (Meyer, 1977; Ferguson and 
Anderson, 1981; Anderson et al, 1982; Going et al, 1988; Potten et al, 1988 and 
Anderson et al, 1989). 
Fibroadenomas appear to be proliferative lesions, but this proliferation has not been 
comprehensively investigated. The effect of hormonal stimuli in relation to 
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pathogenesis, modification of cell proliferation and biological behaviour is unknown 
and the role of natural hormonal changes occurring during the menstrual cycle and 
exogenous hormones require assessment. The putative natural history of 
fibroadenomas also requires investigation to shed further light on the biological 
behaviour of these commonly encountered tumours. 
The main objectives, then, of this study are: 
(i) to test the hypothesis that both the morphology and cell proliferation of the 
fibroadenoma are responsive to hormonal stimulation, 
(ii) to assess morphology and cell proliferation in relationship to patient age in 
order to demonstrate trends in the natural history of fibroadenomas. 
4 
MATERIALS AND METHODS 
Patient Selection 
The clinical data were originally part of a separate clinico-pathological study 
conducted by the Departments of Surgery and Anatomical Pathology of the 
University of Cape Town on 507 women with benign breast disease presenting to the 
breast clinic at Groote Schuur Hospital from 1985 to 1986. Included were 131 
women with 139 histologically confirmed fibroadenomas. At the time of initial 
presentation, a detailed clinical history was taken which especially included the date 
of the last menstrual period, cycle length and regularity and hormonal contraceptive 
use. Knowing the date of the last menstrual period, the day of the menstrual cycle on 
the day of lump excision could be calculated assuming a regular 28 day cycle. 90 
women had menstrual data regarded as suitable for this study. Essential 
requirements were that there was a regular peri 28 day cycle and that not more than 
two cycles had occurred from time of presentation to time of lump excision. 
Morphologic Assessment 
Histology 
Tissues previously fixed in buffered formalin and embedded in paraffin wax were 
obtained from departmental archives. Sections were cut at 4µ from each tissue block 
and stained with haematoxylin and eosin. Sections were also stained with the van 
Gieson stain to assess collagen content. 




Each fibroadenoma was assigned to one of three categories: myxoid, fibrous or 
hyaline. The stroma is considered to have the least amount of collagen when myxoid 
(figure 1), the most when hyaline (figure 3) and intermediate when fibrous (figure 
2). When there was a mixed stromal pattern, the assigned category was that of the 
predominant pattern. 
Stromal Cellularity 
Stromal cellularity was assessed semi-quantitatively according to the method of Kern 
and Clark (1973) and graded on a scale of I to III. Grade I was characterised by 
minimal cellularity, often with hyalinisation (figure 3). Grade II was reserved for an 
intermediate appearance (figure 4) and Grade III (figure 5) was characterised by 
considerable cellularity. 
Epithelial Component 
The epithelial component present within a fibroadenoma was expressed as a 
percentage of total surface area. This was assessed visually with the aid of a lOxlO 
square eyepiece grid, a 4x objective lens and a lOx eyepiece lens. In the estimation, 
allowance was made for spaces made up by glandular lumina. The result was 
expressed to the nearest 5%. 
Stromal Inflammatory Cells 
Sections stained with haematoxylin and eosin were examined for the presence of 
stromal lymphocytes and plasma cells. The Giemsa stain was used to detect stromal 
mast cells. The density of stromal infiltrate of each cell type was assessed and graded 
as follows: Grade I - mild density (scanty cells present), Grade II - moderate density 
and Grade III - marked density. 
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Immunocytochemistry 
Myoepithelial cells were stained immunocytochemically using a mouse monoclonal 
antibody to human alpha-smooth muscle actin (Dako-Smooth Muscle Actin, 1A4 ). 
A separate series of slides was stained for S 100 protein using a polyclonal rabbit 
anti-cow S 100 antibody (Dako ). 
The staining for smooth muscle actin was performed by the avidin-biotin peroxidase 
complex method as follows. 4µm thick sections were cut and mounted onto slides 
coated with 3-aminopropyltriethoxysilane. The sections were incubated for 30 
minutes at 60 °C to promote adherence to the slides. Digestion was performed by 
placing the slides into 0.1 % trypsin (Sigma Laboratories) in TRIS buffer for 7 
minutes at 37 °C. The sections were washed in running tap water for 5 minutes and 
then deparaffinised to 96% alcohol. To block endogenous peroxidase, the sections 
were immersed for 15 minutes in 1 % hydrogen peroxide in methanol. The sections 
were washed in running tap water for 5 minutes and then rinsed in phosphate-
buffered saline. The sections were covered with normal rabbit serum and allowed to 
react at room temperature for 10 minutes. They were then incubated with the 
primary antibody diluted 1:50 with phosphate-buffered saline for 30 minutes. The 
sections were rinsed with phosphate-buffered saline and incubated for 30 minutes 
with the link antibody, biotinylated monoclonal rabbit anti-mouse (Dako) made up 
as follows: 4ml rabbit anti-mouse, 40ml human serum, 956ml phosphate-buffered 
saline. After rinsing the sections in phosphate-buffered saline, they were incubated 
with avidin-biotin-peroxidase complex (Dako) at room temperature for 30 minutes. 
The sections were rinsed in phosphate-buffered saline. 0.03% diaminobenzidine was 
used for colour development followed by counterstaining with Mayer's 
haematoxylin. The sections were washed in running tap water for 5 minutes and then 
dehydrated, cleared and mounted. 
The peroxidase anti-peroxidase method was used for SlOO staining. 4µm thick 
sections were cut, mounted onto slides and deparaffinised to 96% alcohol. 
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Endogenous peroxidase activity was blocked by immersing the sections m 1 % 
hydrogen peroxide in methanol for 15 minutes. The sections were washed in running 
tap water for 5 minutes. A digestion step was performed by placing the slides into 
0.1 % trypsin (Sigma Laboratories) in TRIS buffer for 5 minutes at 37 °C. The 
sections were washed in running tap water :·or 5 minutes. They were then allowed to 
react with normal swine serum (Dako) diluted 1/20 in phosphate buffered saline for 
10 minutes at room temperature. The serum was tapped off and the excess wiped 
away. Overnight incubation with the primary antibody diluted 1/100 at 4 °C 
followed. The slides were washed in phosphate buffered saline for 20 minutes with a 
mechanical stirrer. They were then incubated with the link antibody, Dako swine 
anti-rabbit diluted 1/20 with phosphate buffered saline for 20 minutes at room 
temperature. The slides were washed for 20 minutes in phosphate buffered saline 
using a mechanical stirrer and then incubated with the peroxidase anti-peroxidase 
complex (Dako) for 30 minutes at room temperature. The slides were washed in 
phosphate buffered saline using a mechanical stirrer for 20 minutes. 0.03% 
diaminobenzidine was used for colour development. The slides were rinsed in 
phosphate buffered saline, washed with water, counterstained with Mayer's 
haematoxylin, dehydrated, cleared and mounted. 
The degree of vacuolisation of the stained myoepithelial cell was graded on a scale 
of I to III. Grade I was characterised by little or no vacuolisation (figure 6), Grade II 
by an intermediate degree of vacuolisation (figure 7) and Grade III by marked 
vacuolisation (figure 8). 
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Assessment of Cell Proliferation 
Immunocytochemistry 
The state of cell proliferation of stromal and epithelial cells was assessed by 
immunocytochernical staining for proliferating cell nuclear antigen (PCNA) using 
monoclonal mouse anti-PCNA (Dako-PCNA, PClO). 
The staining was performed by the avidin-biotin peroxidase complex method similar 
to that used for smooth muscle actin. There were, however, several modifications: 
heat was not used to promote adherence of the sections to the glass slides and, 
instead, the slides were left to air-dry overnight. A digestion step was not included. 
The primary antibody was diluted 1:150. 
Case Selection 
PCNA staining was performed on all patients who presented and underwent 
fibroadenoma excision within the same menstrual cycle. Patients were selected from 
the group that was in the second cycle following presentation in order to produce a 
reasonable spread throughout the cycle and as wide an age range as possible. 
Staining was also performed on all patients using an oral contraceptive (OC) or 
Depo-Provera. 
As fixation times were unknown, and as staining can be abolished by prolonged 
fixation time, all cases showing weak or no staining were discarded. Cases that 
showed weak staining at the periphery of the lesion, but good staining more 
centrally, where fixative had presumably penetrated the least, were deemed suitable 
for cell counting purposes. 
Overall, PCNA staining was performed on 37 fibroadenomas. Eight were on an QC 
and 9 were on Depo-Provera. 
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Counting Method 
Cell counting was performed with the aid of a lOxlO square eyepiece grid, at high 
power magnification (lOx eyepiece lens, 40x objective lens). All nuclei showing 
staining, (including weak staining) were counted as positive. Cell counts were 
recorded with a manually operated mechanical counter. All epithelial cells and all 
stromal cells were counted in each field until a total of at least 1000 of both cell 
types was reached. Stromal mononuclear inflammatory cells and endothelial cells 
were not included. Epithelial counts included myoepithelial cells. PCNA index was 
expressed as the percentage of positive cells for the total number of cells counted. 
Each case was selected randomly and counted with no knowledge of clinical or other 
data. Field selection was conducted moving progressively downwards and then 
across the slide. Areas at the periphery where staining was poor were avoided. Each 
fibroadenoma was counted once, although randomly selected fields were recounted' 
(average of 3.4 fields per lesion) to assess reproducibility of the counting method 
(see appendix). 
Statistical Analysis 
Because of marked skewing, the PCNA data were log transformed. The relationship 
between variables was tested using Pearson's correlation coefficient with the Stat 
Graphics package (Statistical Graphics Corporation, 1988). 
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Figure 1. Fibroadenoma with myxoid stroma (H + E x40). 




Fibroadenoma with hyaline stroma showing minimal (Grade I) 
cellularity (H + E x40). 






Fibroadenoma with considerable (Grade III) stromal cellularity 
(H+E xlOO) . 
Myoepithelial cells stained using anti-human smooth muscle actin 




Myoepithelial cells stained using anti-human smooth muscle actin 
showing intermediate (Grade II) vacuolisation (H + E x400). 
Myoepithelial cells stained using anti-human smooth muscle actin 




The age distribution of fibroadenomas in this series is shown in figure 12. There was 
an age range of 15-60 years with a mean age incidence of 24.1 years and a peak 
incidence in the 20-24 year age group. 
Fibroadenoma Size and Patient Age 
The relationship of size and age is shown in figure 13. Fibroadenoma size ranged 
from 0.2 to 7.0cm with a mean size of 2.2cm. Most fibroadenomas greater than 
3.5cm in diameter occurred at 20 years of age or younger. There was a tendency for 
fibroadenomas to decrease in size with increasing patient age (r =-0.177; p = 0.0392). 
Stromal Character and Patient Age 
As shown in figure 14, all fibroadenomas in the 15-19 year age group were either 
myxoid or fibrous with slightly more fibrous than myxoid tumours. In the 20-24 year 
age group, the great majority of fibroadenomas were fibrous; included was a small 
number of hyaline lesions. Cases over 25 years of age were relatively few with mixed 
proportions of myxoid, fibrous and hyaline lesions. Myxoid lesions were noted to 
occur up to the 45-49 year age group. A single fibroadenoma in the 60-64 year age 
group was hyaline. 
Stromal Cellularity and Patient Age 
Figure 15 shows that nearly all fibroadenomas in the 15-19 and 20-24 year age 
groups had Grade II or Grade III cellularity of the stroma with the latter 
predominating. In the 20-24 year age group, a small number of Grade I tumours was 
also present. In the 25-29 year age group there were more Grade II than Grade III 
lesions. From 30-39 years Grade II and III lesions occurred in roughly equal 
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proportions, along with the occasional Grade I tumour. Notably, there was a single 
Grade III lesion in the 45-49 year age group. 
Epithelial Component and Age 
The epithelial component, expressed as a percentage of total surface area, as 
illustrated in figure 16, showed a tendency to decline with age (r=-0.1613, 
p = 0.0596). All values of 35% and greater occurred at 25 years of age or younger. 
Stromal Inflammatory Cell Infiltrate 
Stromal lymphocytes, plasma cells and mast cells were observed in most 
fibroadenomas in variable proportions. In the vast majority of cases, the density of 
infiltrate of each cell type was scored as Grade I. There was no observable 
correlation with any other variable examined. In some fibroadenomas stromal 
eosinophils were noted; in one case, the infiltrate was fairly prominent Stromal 
neutrophils were also present in some cases. 
Myoepithelial Cell Vacuolisation 
As shown in figure 17, there was no observable change in myoepithelial cell 
vacuolisation in phase with the menstrual cycle. Grade I, Grade II and Grade III 
vacuolisation occurred in roughly equal proportions in all quarters of the cycle. 
Grade I vacuolisation predominated. 
Smooth muscle actin 1A4 antibody gave stronger and better defined staining 
compared to SlOO and was the better method for demonstrating myoepithelial cells. 
PCNA Immunoreactivity 
The intensity of PCNA immunoreactivity ranged from weak granular to strong 
diffuse nuclear staining; this variability was observed in most high power counting 
fields (figure 9). Some fibroadenomas showed strong diffuse nuclear staining within 
most nuclei (figures 10 and 11). 
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Generally, high PCNA indices were recorded for both epithelium (mean=64.9%) 
and stroma (mean=67.4%). There was also a marked degree of variability. PCNA 
indices ranged from 24.5% to 95.5% for epithelium and 18.6% to 96.1 % for stroma. 
PCNA indices for epithelium did not correlate with phase of the menstrual cycle 
(figure 18), (r=-0.0721; p=0.7153); neither did stroma (figure 19), (r=0.2869; 
p = 0.1389). Of 28 recorded indices, 23 epithelial and 22 stromal indices were above 
50% with no observable variation in phase with the cycle. 
No correlation of stromal and epithelial indices in phase with the cycle was observed 
when comparing patients using the OC (n=8) and patients not using any exogenous 
hormone (n=20) (figures 18 and 19). Patients using Depo-Provera (n=9) were 
assumed not to be in cycle. PCNA indices for patients using Depo-Provera ranged 
from 36.3% to 91.5% for epithelium and 55.7% to 82.2% for stroma with means of 
68.0% and 72.2% respectively. These values are not observably different when 
compared to those women using an OC or those cycling naturally. One patient on 
Depo-Provera had two fibroadenomas; the indices of the two showed some 
similarity and were 74.9% and 74.2% for epithelium and 70.7% and 82.2% for 
stroma respectively. 
Age did not correlate with PCNA index for epithelium (figure 20), (r=-0.2291; 
p=0.1665) or stroma (figure 21), (r=0.0088; p=0.9580). The lowest indices for 
epithelium and stroma were from a patient aged 43 years; however, indices in other 
patients older than 35, although few in number, were mostly as high as those of 
younger patients. 
The PCNA epithelial/stromal ratio did not correlate with phase of menstrual cycle 
(figure 22), (r=0.01) or with age (figure 23), (r=-0.11). The epithelial stromal ratio 
in the majority of cases ranged between 0.6 and 1.4, indicating that PCNA 
immunoreactivity for epithelium and stroma did not vary greatly. Stroma 
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immediately adjacent to epithelium showed increased staining when compared to 
more distant stroma. 
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Figure 9. Fibroadenoma showing epithelial and stromal PCNA 
immunoreactivity. Nuclei show a variable intensity of staining 
(H+E x400). 
Figure 10. Fibroadenoma showing a high degree of epithelial and stromal PCNA 
immunoreactivity (H + E xlOO). 
Figure 11. 
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High power view of fibroadenoma in Figure 10 showing strong 
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In this series there was a peak incidence of fibroadenomas in the third decade, 
which is in keeping with the findings of others (Foster et al, 1988). While it is 
probable that a proportion of fibroadenomas are never excised, these age incidences 
show that they are rare in post menopausal women. It has also been reported that 
fibroadenomas are seldom encountered in carefully examined mastectomy 
specimens from post menopausal women (Kern and Clark, 1973). It is possible, 
therefore, that fibroadenomas begin in young women as "active" cellular tumours 
and become hyalinised fibrous lesions in later decades. Some may even regress. 
However, the overall assessment of stromal collagen content and stromal cellularity 
in this study did not support the hypothesis that fibroadenomas have such a natural 
history in keeping with breast age. The finding of hyalinised lesions in younger age 
groups suggests that fibroadenomas may have a relatively short natural history and 
not all myxoid or cellular lesions are confined to younger individuals, which may 
indicate that fibroadenomas have the potential to occur ab initio in older women. 
On the other hand, data of this study indicate that fibroadenomas have a tendency to 
be smaller with increasing age and that the epithelial content assessed as a 
percentage of total surface area showed a tendency to decline with age. These 
factors suggest that fibroadenomas are more atrophic with increasing age. This may 
be related to age-related vascular changes. The cell proliferation data, however, do 
not support this and show that PCNA indices of fibroadenomas of older women can 
be just as high as those of younger women, although the numbers were relatively few 
and the sample may not be entirely representative. 
In this study, myoepithelial cell vacuolisation and density of stromal cell infiltrate 
were criteria used for assessing morphologic changes in phase with the menstrual 
cycle. Unlike studies on normal breast, neither criterion showed any cyclic variation. 
The morphologic data, therefore, indicate that fibroadenomas differ in biologic 
behaviour from normal breast. 
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Cell Proliferation 
There have been several recent publications reviewing methodology for assessment 
of cell proliferation (Hall and Levison, 1990; Quinn and ·wright, 1990; Linden et al, 
1992). 
Fundamental to the understanding of cell proliferation is the concept of the cell 
cycle. 
The Cell Cycle 
M phase 
/1-2hrs ~\ ~1------1 
G2 phase G1 phase Go phase Non 
+-
1-6 hrs variable variable proliferative 
~Sphase/ l 
7-12 hrs Death 
During the synthetic or S phase, DNA is synthesized and the genome doubled. The S 
phase is separated from the previous mitosis (M phase) by a variable period known 
as the first gap or G1 phase. Following DNA synthesis there is a second gap or G2 
phase which precedes the next mitosis. Interphase is made up of successive G1, S and 
G2 phases and forms the largest part of the cell cycle. Although still controversial, a 
Go phase has been proposed in which there is a non cycling population of cells that 
can, after suitable stimuli, rejoin the cycling population. In any tissue there will 
always be cycling and non cycling cell compartments. The proliferation fraction of 




Counting mitotic figures is the traditional, oldest and most easily performed method 
to assess cell proliferation. The M phase is the only part of the cell cycle that is 
recognized by this simple morphological examination. Because of its shortness, the 
M phase accounts for the smallest portion of the proliferating cell population. Major 
criticisms are lack of standardization and reproducibility. Variables to be considered 
include high power field area and counting of random high power fields or the most 
mitotically active areas. Delay in tissue fixation allowing mitoses to go to 
completion, and section thickness can lead to variation in measurement, too. 
Observer experience is important and pyknotic nuclei and suspicious cells should not 
be counted. Mitotic rates can be expressed as the number of mitoses per number of 
high power fields, mitoses per square millimeter or mitoses per number of cells 
counted (mitotic index). 
Thymidine La belling 
The incorporation of a labelled DNA precursor, tritiated thymidine, during DNA 
synthesis in the S phase permits direct morphologic assessment of proliferating cells. 
The method, however, requires viable cells in culture as only actively proliferating 
cells will take up the radiolabelled thymidine. Freshly excised tissue is incubated 
with tritiated thymidine for 1-2 hours and is then fixed and routinely processed. 
Autoradiographs are prepared and then developed after one week of exposure. The 
thymidine labelling index (TLI) is determined as the number of positive cells per 
total number of cells counted. 
Main disadvantages are the need to incubate fresh tissue and delay in finished 
product making this procedure unsuitable for routine practical use in histopathology. 
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Bromodeoxyuridine Incorporation 
5-Bromodeoxyuridine (BrdU) is a thymidine analogue and shares many of the 
technical requirements and disadvantages of thyrnidine labelling. The BrdU assay, 
however, does not require radiolabelling or autoradiography. Monoclonal antibodies 
to BrdU have been developed and cells in the S phase can be identified by 
immunocytochernistry, irnmunofluorescence or flow cytometry and this reduces 
delay. Studies comparing thyrnidine labelling and BrdU incorporation have shown 
identical results (Meyer et al, 1989). 
Immunocytochemical Methods 
Antibodies have become an important means of assessing cell proliferation. In 
addition to their use in the bromodeoxyuridine assay, they can detect a variety of cell 
proliferation-related proteins. These antigens are not necessarily related to the same 
component of the cell cycle. A major advantage is that, because tissue sections are 
being used, the spacial orientation of the proliferating cell fractions can be assessed. 
This can be applied to different phenotypic cell populations, either by simple 
morphologic means or by double-staining irnmunocytochemical methods. These 
methods are static in that they measure the "state" rather than the "rate" of cell 
proliferation. 
Ki-67 
This is perhaps the best known antibody recognising proliferating cells. It is a mouse 
monoclonal antibody raised against a crude nuclear fraction of a Hodgkin's disease 
d~rived cell line by Gerdes et al, (1983) in Kiel. It detects an unidentified antigenic 
epitope of a proliferation-associated nuclear protein. Expression is from Mid-G1 
phase and throughout S, G2, and M phases. A major disadvantage for routine use 
has been the requirement of fresh tissue for cryostat preparations. However, a 
monoclonal antibody, MIB1 has recently been developed that is suitable for use in 
formalin-fixed paraffin-embedded tissue (Gerdes et al, 1992). 
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Proliferating Cell Nuclear Antigen (PCNA) 
PCNA ( also known as cyclin) is a stable 36kD nuclear protein that has been 
identified independently by several groups and given different names. Miyachi et al, 
(1978) identified autoantibodies reactive with nuclear antigens in proliferating cells 
in the sera of patients with systemic lupus erythematosus. Celis et al, (1984) 
characterised a nuclear protein, cyclin, by two dimensional gel electrophoresis in 
proliferating and quiescent cells. Mathews et al, (1984) found that PCNA and cyclin 
are identical nuclear proteins. 
PCNA functions as a cofactor for DNA polymerase delta. Lee and Hurwitz, (1990) 
have demonstrated that in the presence of single-stranded-DNA-binding protein, the 
elongation of primed DNA templates by DNA polymerase delta is dependent upon 
ATP and two protein factors, activator 1 (Al) and proliferating cell nuclear antigen. 
Al, PCNA and DNA polymerase delta form a stable complex in the presence of 
ATP that can be isolated by gel filtration. The binding of PCNA to the Al DNA 
polymerase complex is ATP dependent. 
It is stated that PCNA levels increase rapidly in mid-G 1, remain elevated throughout 
S phase, and begin to decrease from G2/M to G 1 (Linden et al, 1992). Morris and 
Mathews (1989), however, assayed PCNA in synchronised HeLa cells by two 
dimensional gel electrophoresis. They demonstrated an increase in the rate of 
PCNA synthesis with a peak in early S phase, but the magnitude of the increase was 
only 2-3 fold. Throughout the cell cycle, the ratio of PCNA to total cell protein 
remained constant. They also observed that up to one third of total PCNA is tightly 
associated with the nucleus, presumably in replication complexes at the peak of the 
cell cycle. They concluded that cyclic synthesis of PCNA is in excess of the amount 
involved directly in DNA replication and that the amount of protein neither 
fluctuates significantly with the cell cycle nor is limiting for DNA synthesis. 
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Recently, several commercially available antibodies to PCNA have become 
available for formalin-fixed, paraffin embedded tissue sections. This has obvious 
advantages and recently numerous PCNA-related investigations have been 
published in the literature. PCNA staining is confined almost entirely to the nucleus 
with a diffuse or granular pattern, or with a mixture of both. During mitosis, there is 
diffuse cytoplasmic staining attributable to loss of nuclear membrane. Some mitotic 
figures, however, have been noted to stain negatively (Hall et al, 1990). 
PCNA has a half life of about 20 hours (Bravo et al, 1987) and, therefore, may be 
detectable in cells that have recently left the cell cycle. PCNA immunoreactivity is 
markedly reduced if heat is used to promote adherence of sections to glass slides 
(Hall et al, 1990). PCNA immunoreactivity is present in tissues fixed in a wide range 
of solutions including formalin, Bouin's reagent and methacarn. Fixation time is of 
importance. Hall et al, (1990) have observed that staining is greatly reduced after 48 
hours and is virtually abolished after 72 hours. They also state that protease 
digestion is not necessary to unmask antigen and may even reduce immunoreactivity. 
Hall et al (1990) examined PCNA staining in a variety of non neoplastic tissues. 
They found positive staining in tissues known to be actively· proliferating with a 
spacial relationship as would be expected. Examples included staining in germinal 
centres of lymphoid tissue, staining in the basal layer of stratified squamous 
epithelium and staining in the crypt epithelium of gastrointestinal mucosa. PCNA 
staining was minimal in tissues known to be non-proliferative, such as peripheral and 
central nervous system and smooth, skeletal and cardiac muscle. 
Reports in the literature indicate that assessment of PCNA immunoreactivity is a 
valid method that has correlated well with other methods for assessing cell 
proliferation (Garcia et al 1989; Woods et al 1990; Kamel et al 1991 and Dervan et al 
1992). 
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Battersby and Anderson (1990), in 47 cases of normal resting breast tissue, found a 
highly significant correlation between PCNA staining with antibody 19A2 and 
tritiated thymidine labelling, (tau = 0.748, p = 0.00003). They concluded that PCNA 
localisation provided a useful index of DNA synthesis and cell proliferation in 
breast. 
Hall et al (1990), using a double labelling method, demonstrated a general 
concordance between PCNA immunoreactivity and tritiated thyrnidine labelling in 
cultured human keratinocytes and in 16 non Hodgkin's lymphomas. There was a 
linear relationship between Ki-67 and PCNA (PC10) staining, (r = 0.91). 
Some studies, however, have shown poor correlation of PCNA with other methods 
for assessing cell proliferation. Jain et al, (1991) found a poor correlation between 
PCNA index and flow cytometric evaluation of S phase in 93 cases of gastric cancer. 
Yu et al (1991), in 42 cases of haemangiopericytoma, also found no correlation 
between PCNA index and S phase fraction. Leonardi et al, (1992) in a series of 106 
breast carcinomas found that PCNA (PC10) index did not correlate with Ki-67 index 
or any other variable examined. Hall et al (1990) suggest that poor correlation 
between S phase fraction and PCNA staining may be due, in part, to the long half 
life of PCNA. Hall et al (1990) also suggest that, in certain neoplasms, there is 
deregulation of PCNA gene expression by autocrine or paracrine secretion of 
growth factors, such as platelet derived growth factor. Increased PCNA staining has 
been noted in normal tissue surrounding some breast and pancreatic tumours, 
possibly due to the paracrine influence of growth factors elaborated by the tumour. 
These growth mechanisms may increase messenger RNA half-life with a resultant 
increase in PCNA levels (Hall et al 1990). Injection of human carcinoma cell lines in 
vivo into the liver and kidney of nude mice and infusions of growth factors into rats 
have given rise to an increase in PCNA (PC10) immunoreactivity with no change in 
the number of S phase cells. PCNA immunoreactivity can occur, therefore, without 
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cell proliferation in association with neoplasia, and this may be mediated by growth 
factors in vivo (Hall et al, 1992). 
In establishing a method of evaluating and sconng imrnunostaining, several 
problems arise. In many tissues, imrnunostaining is heterogeneously distributed. 
There is no clarity whether one should restrict counting to histological fields showing 
the most positive staining, or whether there should be random selection. PCNA 
staining is variable in intensity and there is no clarity either whether one should 
count all positive cells, including weakly positive cells, or only strongly positive cells. 
To date there is no universally accepted standardised method for histological field 
selection and quantitation of imrnunostaining. Results from different centres are, 
therefore, often not comparable (Linden et al, 1992). McGurrin et al (1987) using 
Ki-67 imrnunostaining in breast carcinomas reported a mean index of 22% (per 1000 
cells) counting areas with the most dense immunostaining. In contrast, Wrba et al 
(1989) counted Ki-67 immunolabelling in breast carcinomas using random field 
selection and reported a mean index of 7.2% (per 1000 cells). 
Battersby and Anderson (1990) compared thymidine labelling index and PCNA 
imrnunoreactivity in 47 cases of normal resting breast tissue and commented on 
variability in strength of PCNA nuclear staining. When only strongly reactive nuclei 
were counted, values very similar to tritiated thymidine labelling were obtained, but 
if weakly staining nuclei were counted as well, values were approximately 30% 
higher. 
In this study, all stained nuclei, including those weakly stained, were counted. 
Although the resulting PCNA indices were higher, this method reduced the level of 
uncertainty in deciding between positive and negative nuclei. This also allowed for 
consistency in comparing fibroadenomas within the same study and no attempt was 
made to compare the results of other studies. Fields for cell counting were not 
selected for any particular density of stained nuclei. A minimum of 1000 stromal and 
epithelial cells were counted. Using binomial parameters it has been calculated that 
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if 1000 cells are counted for a 95% confidence level, the margin of error would be 
3% (Linden et al 1992). In this study, repeat counting indicated a high level of 
reproducibility of the cell counting method. 
Generally the stromal and epithelial cells of the fibroadenoma exhibited a high 
degree of PCNA immunoreactivity. In some cases the indices were of the order of 
90%. These values are far greater than TLI and PCNA indices encountered in 
studies on normal resting human breast. Unfortunately, in this study, the amount of 
normal breast tissue surrounding the fibroadenomas was inadequate for an internal 
control. Counting all stained nuclei is almost certainly a contributing factor to this 
high index. As illustrated, however, (figures 10 and 11) some fibroadenomas showed 
a very high index of strong nuclear staining, even in the face of relatively few mitotic 
figures. Several explanations are possible: 
(i) PCNA has a long half life and may still be present in cells that have left the 
cell cycle. 
(ii) Morris and Mathews (1989) have shown that PCNA is present throughout the 
cell cycle and PCNA is in excess of requirements for DNA synthesis. 
(iii) Fibroaderiomas are· in fact actively proliferating tesions with most cells 
forming the cycling cell compartment. 
(iv) The cells may have a long cell cycle with a prolonged G1 phase. Few cells are 
in Go. 
(v) Hall et al (1992) have shown that non-cycling cells can express PCNA, 
possibly as a result of growth factor stimulation. 
Tritiated thymidine labelling has been used by several groups to assess cell 
proliferation in normal lobular epithelium (Meyer 1977; Anderson et al 1982; Going 
et al 1988; Potten et al 1988). All investigations demonstrated a significant cyclic 
variation of TLI with a peak late in the second half of the menstrual cycle. Most 
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studies found no effect of OC on cell proliferation in breast epithelium (Meyer 1977; 
Anderson et al 1982; Going et al 1988; Patten et al 1988). Anderson et al (1989) 
found significantly higher mean TLI values in late proliferative and late secretory 
phases of women with OC regulated cycles when compared to women with natural 
cycles. 
In these studies a significant decline of TLI with age was also observed. In assessing 
the effect of breast age (duration between menarche and time of biopsy) it was 
found that breast epithelium from very young women (less than 5 years breast age) 
was more proliferative than that of older women (Anderson et al 1989). 
However, there remains a marked paucity of existing understanding of normal 
breast development and the numerous factors that influence the proliferation of 
normal breast epithelium. In the past, it has been suggested that oestrogen 
stimulates proliferation of breast epithelium and that progestins are associated with 
differentiation and secretion in keeping with the misconception that regulation of 
breast proliferation and differentiation is similar to that occurring in the 
endometrium. The demonstration of increased proliferation of breast epithelium 
fairly late in the second half of the cycle contradicts this. It is possible that the 
differences between breast and endometrial proliferation reflect differences in 
receptor status. Anderson et al (1989) state that oestrogen is a mitogen for 
endometrium, but not for breast. Oestrogen may facilitate progestin action by 
increasing progesterone receptor levels. Proliferation and development of breast 
epithelium is obviously a complex process and hormones may alter the effect of a 
host of "growth factors", either by influencing growth factor secretion or by changing 
receptor activity (McCarty, 1989). The interactions of these effectors of 
development have barely been characterised. The secretion of a number of growth 
factors, including insulin-like growth factor and transforming growth factor-alpha 
can be modified by oestrogens (McCarty, 1989). 
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Unlike the various cell proliferation studies on normal human breast, the cell 
proliferation data of this study, expressed as PCNA immunoreactivity, show no 
correlation with the menstrual cycle. Exogenous hormones, in the form of OC 
agents or injectable progestogen, do not appear to exert any effect either. This study 
does indicate that fibroadenoma is a highly proliferative lesion. This is in keeping 
with its fairly rapid growth and increase in size. 
The high level of proliferative activity of fibroadenomas and their apparent lack of 
response to hormonal stimuli indicates that these lesions exhibit some degree of 
autonomous biological behaviour. This may be due to a localised paracrine or 
autocrine influence, possibly related to changes in receptor or growth factor status. 
Wilkinson and Forrest (1985) state that the fibroadenoma represents a group of 
hyperplastic breast lobules, but the lack of response to hormones demonstrated in 
this study may rather indicate a neoplasm. Autocrine influences such as epithelial-
stromal interactions may play an important role. In this study, the stroma generally 
exhibited as high a degree of PCNA immunoreactivity as the epithelium. Although 
not quantitated, the stromal cells immediately adjacent to epithelium were observed 
to have a higher degree of immunoreactivity than those stromal cells further away. 
This suggests some kind of interaction at the stromal-epithelial interface, possibly 
mediated by growth factors. 
Unlike declining proliferative indices observed in normal breast with increasing age, 
PCNA immunoreactivity did not correlate with patient age. High PCNA indices 
occurred in fibroadenomas of older women, although one did show low indices. This 
is in keeping with the finding of myxoid or cellular "active" appearing lesions in older 
age groups. Fibroadenomas, therefore, appear to retain their ability to proliferate 
beyond the third decade, although in terms of age incidence, this ability becomes 
increasingly limited. High PCNA indices of fibroadenomas in older women are in 
contradiction to the morphologic data that show a tendency for fibroadenomas to 
decrease in size and epithelial component with age. This may be due to skewing of 
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PCNA data produced by the small PCNA sample number. Falsely high PCNA 
indices for the various reasons already mentioned may also be of importance. 
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CONCLUSION 
The hypotheses initially stated are not supported by this study. There are no 
morphologic changes in fibroadenomas related to hormonal stimulation in terms of 
the menstrual cycle or hormonal contraceptive. 
Cell proliferation in fibroadenomas shows no relationship to steroid stimulation, but 
there may be limitations to the methodology used as discussed by Hall et al (1992). 
A true alternative method would be to perform in vitro studies on cells from the 
fibroadenoma in culture and assess the effect of steroids on tritiated thymidine 
labelling. 
A strong age-related incidence of fibroadenomas has been demonstrated. Although 
cell proliferation showed no relationship to age, fibroadenoma size and epithelial 
component both showed a tendency to decline with age that was not statistically 
significant. Fibrous lesions are commoner in younger age groups. However, if one 
presumes that young lesions are myxoid and hyaline lesions are old, then this study 
indicates that young fibroadenomas can occur in older women. The only true way to 
show a natural history would be to design a study in which fibroadenomas are left in 
situ within the breast for varying periods of time ( even possibly years), but this would 
probably not be ethically permissible. 
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APPENDIX 
PCNA Index Assessment: 
Each line represents a counting of a single lOxlO square grid at 
high power with positive and negative epithelial and stromal cells. 
Numbers in brackets are recounts of the number immediately above. 
PATIENT EPITHELIUM STROMA 
SD NO. 
+VE -VE TOTAL +VE -VE TOTAL 
11684/86 91 53 144 64 111 175 
134 80 357 76 79 320 
(72) (75) 
146 106 610 67 64 451 
170 109 889 79 97 627 
(84) (98) 
81 48 1018 84 112 818 
142 94 1254 110 181 1109 
11717/85 157 84 241 31 36 67 
184 98 523 64 74 205 
107 85 715 99 92 396 
109 104 928 77 101 574 
113 64 1105 69 81 724 
79 81 1265 84 121 929 
(80) (88) 
129 93 1487 65 73 1067 
15213/86 1 64 139 203 21 130 151 
97 130 430 49 66 266 
101 129 660 40 92 398 
50 84 794 43 64 505 
67 107 968 40 71 616 
78 115 1161 28 64 708 
(74) (99) 
57 112 1330 49 55 812 
(57) (58) 
23 68 1421 51 73 936 
56 50 1527 42 71 1049 
14922/86 41 111 152 94 35 129 
63 92 307 112 33 274 
57 70 434 133 31 438 
35 65 534 78 44 560 
(83) (39) 
55 92 681 96 30 686 
48 116 845 101 15 802 
37 63 945 74 14 900 
54 75 1074 117 15 1022 
16108/85 127 103 230 54 40 94 
66 46 342 76 59 229 
92 46 480 70 44 343 
( 67) (49) 
104 81 665 70 45 458 
(108) (92) 
95 81 841 82 47 587 
73 70 984 67 39 693 
(69) ( 67) 
74 64 1122 46 40 779 
72 71 1265 63 48 890 
79 60 1404 67 85 1042 
(70) (84) 
3713/86 164 25 189 122 16 138 
190 42 421 
(206) (27) 
185 55 661 84 27 359 
127 25 813 147 37 543 
100 17 930 141 19 543 
162 9 1101 130 13 846 
142 11 1254 125 6 977 
147 22 1423 129 24 1130 
9562/85 94 74 168 115 50 165 
141 137 446 83 30 278 
127 116 689 63 36 377 
169 133 991 41 34 412 
137 76 1204 69 47 528 
68 72 1344 76 34 638 
145 72 1561 61 36 735 
(167) (89) 
96 62 1719 103 43 881 
(88) (56) (94) (48) 
57 39 1815 121 72 1074 
1075/86 127 26 153 113 15 128 
79 80 312 114 90 332 
157 48 517 103 21 456 
(175) (47) 
186 48 751 81 11 548 
172 31 954 120 18 686 
96 19 1193 129 16 978 
127 31 1351 71 34 1083 
12292/85 105 85 190 82 31 113 
153 41 384 88 32 233 
81 31 496 72 53 358 
229 97 822 68 43 469 
156 139 1117 45 44 558 
(154) (148) 
161 117 1395 51 57 666 
40 51 1486 58 57 781 
(40) (47) 
64 38 1588 33 76 890 
(61) (43) 
55 42 1685 49 28 967 
(47) ( 31) 
93 55 1833 47 60 1074 
(86) (56) 
10224/85 120 49 169 54 80 134 
99 29 297 105 63 302 
129 74 500 65 ::"11 418 
97 26 623 88 69 575 
116 46 785 66 51 692 
(106) (50) 
131 69 985 97 56 845 
85 31 1101 112 82 1039 
18377/85 88 32 120 67 25 92 
115 46 281 105 26 223 
(117) (50) 
140 42 463 77 17 317 
128 49 640 88 18 423 
92 39 771 92 38 553 
119 53 943 107 16 676 
106 38 1087 96 12 -784 
78 11 1176 106 18 908 
91 22 1289 112 14 1034 
2268/86 95 95 190 59 34 93 
61 71 322 73 78 244 
93 72 487 52 63 359 
88 75 650 69 97 525 
(88) (69) 
82 22 754 75 38 638 
98 45 897 75 28 741 
(95) (41) 
88 28 1013 89 27 857 
94 62 1169 54 58 969 
(59) (57) 
74 54 1297 66 62 1097 
18377/85 L 92 28 120 11 4 15 
64 22 206 23 9 47 
7 10 223 37 21 105 
17 6 246 34 35 174 
59 26 331 32 23 229 
64 24 419 56 25 310 
(68) (20) 
47 23 489 62 23 395 
82 54 625 8 22 425 
100 31 756 31 12 468 
28 4 788 83 16 567 
61 8 857 72 11 650 
93 33 983 54 23 727 
(92) (39) 
93 20 1096 65 9 801 
49 17 1162 69 11 881 
78 20 1260 47 18 946 
(74) (19) 
49 4 1313 30 14 990 
8605/85 72 26 98 66 55 121 
69 118 285 45 87 253 
107 63 455 40 89 382 
172 137 764 46 56 484 
(175) (148) 
98 68 930 44 71 599 
119 116 1165 73 67 739 
(113) (116) 
105 103 1373 48 51 838 
100 69 1542 47 57 942 
(92) (77) 
78 42 1662 57 64 1063 
5194/86 89 53 142 54 39 93 
158 80 380 85 51 229 
102 53 535 113 53 395 
120 54 
112 51 698 77 69 541 
(71) (63) 
129 20 847 138 16 695 
109 52 1008 92 40 827 
12045/86 153 72 225 44 89 133 
154 36 415 52 68 253 
82 44 541 66 129 448 
124 37 702 87 88 623 
146 37 885 82 66 771 
103 23 1011 62 98 931 
152 35 1198 94 80 1105 
8442/86 117 55 172 117 30 146 
93 33 298 152 36 335 
114 51 463 99 14 448 
153 48 664 117 26 591 
181 48 893 114 44 749 
(186) (38) 
108 24 1025 136 38 923 
101 24 1150 162 21 1106 
6728/86 59 52 111 93 35 128 
80 59 250 · 100 18 246 
69 51 370 101 22 369 
50 43 463 70 20 459 
110 45 618 105 35 599 
(103) (47) 
88 54 760 79 44 722 
(96) (50) 
60 43 863 71 36 829 
60 58 981 89 24 942 
37 32 1050 70 30 1042 
4987/85 152 93 245 61 25 86 
156 93 494 75 15 176 
54 39 587 108 15 299 
136 93 816 81 18 398 
108 84 1008 76 27 501 
69 76 1153 72 36 609 
118 85 1356 79 19 707 
80 55 1491 101 17 825 
37 27 1555 92 16 933 
99 30 1684 96 23 1052 
10286/86 167 13 180 107 20 127 
100 4 284 138 26 291 
170 13 467 99 25 415 
150 21 638 86 29 530 
121 10 769 166 38 734 
120 4 893 155 18 907 
113 17 1023 166 13 1086 
123 17 1163 158 12 1256 
2268/86 R 151 41 192 93 83 176 
151 16 359 135 56 367 
(150) (15) 
225 60 644 99 47 513 
145 11 800 123 26 662 
178 16 994 109 36 807 
173 32 1199 92 20 919 
117 19 1335 128 31 1078 
(124) (24) 
16852/85 32 111 143 63 95 158 
62 119 324 64 60 282 
76 97 497 75 85 442 
62 70 629 62 100 604 
(66) (68) ( 60) (107) 
55 Bl 765 84 118 806 
61 116 942 58 87 951 
94 98 1134 64 47 1062 
13125/86 39 80 119 4 83 87 
42 113 294 16 60 163 
48 78 420 18 67 248 
29 166 615 8 76 332 
( 9) (78) 
32 130 777 6 83 421 
23 50 850 5 72 498 
(25) (50) 
30 76 956 41 70 609 
(36) (70) 
76 148 1180 46 54 709 
(76) (157) 
15 99 1294 10 79 798 
(12) (79) 
19 112 1425 8 68 874 
32 99 1556 13 73 960 
21 76 1653 20 66 1046 
14630/86 103 216 319 55 65 120 
39 92 450 90 106 316 
51 167 668 107 100 523 
70 199 937 131 65 719 
85 101 1123 81 88 888 
83 132 1338 84 75 1047 
18005/85 101 112 213 57 9 66 
64 86 363 52 23 141 
40 71 473 55 21 217 
77 55 605 48 10 275 
75 45 725 40 10 325 
115 40 880 42 32 399 
83 21 984 42 5 446 
73 54 1111 75 17 539 
51 57 1219 54 23 616 
91 60 1370 35 16 666 
139 63 1572 50 15 731 
49 16 1637 72 28 831 
83 26 1746 64 20 915 
52 25 1823 86 15 1016 
8681/85 260 86 346 44 9 53 
154 53 553 62 21 136 
127 55 735 45 14 195 
106 45 886 61 16 272 
155 39 1080 69 18 354 
187 52 1319 49 12 420 
151 29 1499 67 13 500 
167 59 1725 53 12 565 
182 78 1985 49 17 631 
192 32 2209 57 11 699 
145 47 2401 61 20 780 
97 31 2529 50 11 841 
87 27 2643 64 24 929 
153 33 2829 60 12 1001 
7722/86 174 39 213 71 31 102 
95 27 335 58 21 181 
66 12 433 54 24 259 
115 13 561 74 20 353 
117 18 696 80 27 460 
99 27 822 55 11 526 
105 19 946 53 31 610 
(111) (18) 
127 68 1141 86 41 737 
82 41 1264 78 29 844 
193 35 1492 54 9 907 
147 21 1660 70 20 997 
52 17 1729 50 21 1068 
8072/86 7Q 68 144 55 29 84 
113 67 324 35 38 157 
103 67 495 46 7 210 
106 68 643 44 10 264 
90 29 762 65 15 344 
(95) (30) 
58 15 835 53 10 407 
107 49 991 37 13 457 
51 14 1056 46 13 516 
55 6 1117 56 10 586 
58 15 1190 61 3 646 
71 38 1299 37 8 691 
73 37 1409 32 4 727 
46 37 1492 42 8 777 
(46) (33) 
37 21 1550 40 1 818 
43 25 1618 45 6 869 
85 28 1731 39 6 914 
70 25 1826 35 5 954 
82 22 1930 50 3 1007 
3235/86 190 34 224 112 9 121 
107 65 396 84 10 215 
197 12 605 49 21 285 
89 21 715 130 12 427 
213 54 982 85 8 520 
142 26 1150 149 15 684 
(144) (30) 
148 23 1321 85 9 778 
134 24 1479 116 9 903 
81 16 1576 137 6 1046 
14569/86 92 20 112 57 14 71 
83 21 216 55 24 150 
90 34 340 57 20 227 
72 38 450 67 14 308 
101 36 587 46 17 371 
8.6 21 694 61 18 450 
75 27 796 66 21 537 
97 18 911 86 18 641 
(96) (21) 
112 49 1072 59 12 712 
(112) (49) 
96 51 1219 66 24 802 
64 18 1301 115 26 943 
47 10 1358 67 19 1029 
1338/86 183 23 206 25 28 53 
141 22 369 30 31 114 
126 22 517 44 28 186 
103 17 637 49 20 255 
91 10 738 29 24 308 
47 5 790 37 14 359 
137 22 949 41 15 415 
131 14 1094 31 18 464 
65 5 1164 49 32 545 
84 12 1260 41 18 604 
79 16 1355 40 10 656 
101 12 1468 45 25 724 
104 11 1583 58 13 797 
92 6 1681 63 10 868 
141 12 1840 49 13 930 
182 19 2041 41 15 986 
75 5 2121 43 12 1041 
4692/86 140 12 152 138 8 146 
119 19 290 101 5 252 
130 8 428 157 10 419 
120 20 568 112 2 533 
106 1 675 106 4 643 
141 10 826 142 1 786 
188 20 1034 166 8 960 
(189) (22) 
147 9 1190 121 4 1085 
(121) (4) 
17962/85 143 20 163 50 8 58 
190 21 374 69 13 140 
120 21 515 65 5 210 
109 6 630 97 10 317 
183 32 845 99 36 452 
122 23 990 72 18 542 
159 21 1170 65 9 616 
(153) (22) 
106 11 1287 54 14 684 
122 24 1433 84 12 780 
14631/86 48 61 109 43 17 60 
35 59 203 21 14 95 
75 97 375 14 17 126 
43 36 454 42 5 173 
41 56 551 20 16 209· 
40 53 644 49 6 264 
37 39 720 32 9 305 
(38) (37) 
54 59 833 35 7 347 
44 48 925 32 8 387 
38 55 1018 37 10 434 
(38) (54) 
60 71 1149 38 5 477 
48 40 1237 35 3 515 
41 45 1323 35 10 540 
(44) (43) 
57 58 1438 47 12 619 
(52) (56) 
37 62 1537 57 15 691 
29 34 1600 32 14 737 
52 72 1724 37 11 785 
12893/86 71 62 133 85 47 132 
181 159 473 97 25 254 
135 128 736 112 48 414 
158 66 960 143 31 588 
96 78 1134 81 80 749 
125 34 1293 107 33 889 
(131) (30) 
92 89 1474 129 38 1056 
5691/86 98 9 107 78 10 88 
133 8 248 99 7 194 
148 29 425 81 4 279 
64 36 525 103 11 393 
(68) (36) (101) ( 11) 
101 25 651 92 24 509 
(97) (30) 
116 13 780 126 11 646 
132 12 924 93 6 745 
112 17 1053 87 11 843 
177 21 1251 170 6 1019 
14047/85 111 3 114 152 9 161 
107 9 230 103 18 282 
153 6 389 145 8 435 
148 7 544 90 5 530 
103 2 649 128 6 664 
161 6 816 110 8 782 
146 8 970 93 3 882 
176 9 1155 95 2 979 
88 6 1249 65 2 1046 
(83) (9) 
955/86 106 64 170 56 26 82 
(109) (60) 
201 108 479 49 17 148 
175 105 759 40 8 196 
110 155 1024 25 25 246 
64 99 1187 51 15 312 
53 53 1293 89 5 406 
45 91 1429 72 9 487 
69 87 1585 122 7 616 
57 17 1659 91 2 709 
80 24 1763 97 9 815 
PATIENT AGE CONTRA- CYCLE MYOEP. STROMAL 
SD NO. CEPTIVE DAY VACUOL.CHARACT. 
1833/86 20 21 1 M 
17606/85 17 5 1 M 
13653/85 35 28 1 M 
7432/86 29 18 1 F 
4987/85 26 DEPOT 1 M 
819/86 32 10 1 M 
10224/85 19 27 1 F 
15851/86 30 18 1 F 
14629/85 21 25 2 F 
17962/85 28 oc 2 F 
2848/86 23 20 2 F 
14569/86 32 6 1 M 
17976/86 60 1 H 
6071/86 23 24 1 F 
925/86 18 oc 16 1 F 
7003/86i 21 22 1 F 
7003/86ii 21 22 1 F 
16392/85 19 19 1 M 
1338/86 22 oc 7 3 F 
11062/85 23 13 1 M 
12292/85 23 oc 10 1 M 
15607/85 20 17 1 F 
16247/85 21 12 2 H 
7722/86 26 11 1 F 
18377/851 24 DEPOT 2 H 
18377/85R 24 1 F 
17580/86 19 F 
2654/87 27 DEPOT 2 H 
15470/86 36 5 2 M 
5935/86 22 3 F 
8072/86 28 27 2 M 
955/86 38 10 3 H 
14976/85 18 11 1 M 
10257/86 17 2 M 
10668/85 22 6 ·3 F 
16875/85 23 4 2 F 
18115/86i 15 7 1 F 
18115/86ii 15 7 1 M 
2092/86i 19 2 F 
12145/86 21 8 2 F 
5135/86 25 17 2 M 
8681/85 16 18 3 F 
14630/86 25 18 1 F 
4692/86 21 20 1 M 
3713/86 18 22 3 F 
8605/85 17 DEPOT 2 M 
1293/86 34 3 F 
11523/86 17 18 1 M 
14631/86 42 4 1 M 
7403/86 17 1 M 
7404/86 24 22 ') F "-., 
13125/86 43 24 1 H 
1685/86 26 23 1 F 
11684/86i 21 24 F 
11684/86ii 21 24 2 M 
10589/89 23 20 2 M 
17932/86 25 18 1 M 
1492/86 19 20 1 M 
328/86 36 1 M 
13129/86 21 24 1 F 
2069/86 25 oc 28 1 H 
9756/85 46 DEPOT 2 M 
17722/86 17 1 M 
5691/86 18 13 1 M 
11446/85 19 1 2 F 
957/86 34 25 1 F 
16997/86 29 1 1 F 
11967/85 20 18 2 F 
1316/86 19 oc 2 F 
15294/86 21 1 F 
13827/85i 22 1 F 
13827/85ii 22 F 
8832/85 16 22 3 F 
10414/85 16 8 1 F 
17871/86 24 3 2 F 
9562/85 24 oc 20 2 F 
13131/85 21 M 
6927/86 47 10 1 F 
17588/86 19 1 F 
8442/86 31 DEPOT 3 F 
16106/86 20 15 2 M 
12151/85i 18 1 M 
12151/85ii 18 1 F 
2415/87 22 3 M 
3482/86 16 27 F 
3296/87 24 DEPOT 2 M 
3716/86 26 7 1 M 
10395/86 19 1 F 
9558/85 27 1 M 
11717/85 23 oc 27 2 F 
14515/85 36 10 1 F 
18243/86 37 18 2 M 
1222/86 32 DEPOT 1 M 
3235/86 20 21 1 F 
1709/86i 16 1 M 
1709/86ii 16 2 M 
14922/86 25 DEPOT 1 M 
4136/86 18 3 1 M 
4166/86 18 1 F 
1075/86 18 23 1 F 
2268/86R 21 DEPOT 2 F 
2268/86L 21 DEPOT 1 F 
188/86 21 2 F 
18005/85 21 28 1 H 
1319/86 24 DEPOT 1 H 
859/86 28 8 F 
12045/86 23 23 F 
1741/87 21 16 1 M 
12893/86 20 4 F 
9912/86 19 2 F 
1145/87 35 3 F 
17530/86 18 7 2 M 
18246/86 18 3 F 
9200/86 30 28 1 F 
15875/85 14 3 F 
5194/86 36 10 3 F 
8163/86 28 F 
4806/86 46 25 F 
15213/85 17 24 F 
1980/87 20 1 F 
·. 5543/86 26 1 F 
11297/85 23 oc 11 F 
8855/86 19 25 1 F 
10286/86 39 DEPOT 2 F 
6728/86 24 oc 11 F 
14919/85 23 17 1 M 
14610/85 22 24 F 
17828/86 20 2 F 
16852/85 21 oc 7 2 F 
14047/85 21 7 2 F 
17253/85 26 20 2 F 
5917/86i 20 M 
5917/86ii 20 3 M 
11063/85 16 6 2 M 
12896/86 17 11 2 M 
11918/86 41 3 M 
17021/85 32 1 F 
17610/85 23 22 2 F 
16108/85 24 oc 17 1 F 
AVERAGE 24. 
PATIENT EPITHELIAL SIZE EPITH STROM 
COMPONENT% cm INDEX INDEX 
1833/86 30 1 
17606/85 5 1 
13653/85 5 2 
7432/86 20 ,, L, 
4987/85 50 59.9 79.9 
819/86 30 1 
10224/85 25 70.6 56.5 
15851/86 15 
14629/85 20 2· 
17962/85 20 87.5 84 
2848/86 10 
14569/86 5 74.7 77.9 
17976/86 5 1 
6071/86 30 2 




1338/86 40 7 89 68.7 
11062/85 10 1 
12292/85 15 0.5 62 55.2 
15607/85 10 0.5 
16247/85 5 2 
7722/86 25 1 80.5 73.3 
18377/851 5 74.9 70.7 
18377/85R 10 74.2 82.2 
17580/86 10 1 
2654/87 5 2 
-15470/86 5 1 
5935/86 10 
8072/86 5 68.7 81.2 
955/86 0.5 54.4 84.8 
14976/85 10 3 
10257/86 10 2 
10668/85 50 2 




12145/86 30 2 
5135/86 10 1 
8681/85 25 2 76.5 79 
14630/86 10 32.2 52.3 
4692/86 5 0.5 91. 6 96.1 
3713/86 10 10 85.5 85.4 
8605/85 10 1 55.4 43.8 
1293/86 10 
11523/86 15 
14631/86 5 .3 45.2 77.2 
7403/86 5 2 
7404/86 5 1 
13125/86 5 1 24.5 18.6 
1685/86 10 0.5 
11684/86i 35 2 60.9 42.8 
11684/86ii 5 2 
10589/89 5 
17932/86 10 1 
1492/86 10 
328/86 5 1 
13129/86 10 5 
2069/86 20 1 
9756/85 10 0.5 
17722/86 10 
5691/86 10 0.5 86.4 91.1 
11446/85 10 1 
957/86 5 r, .c., 
16997/86 10 
11967/85 10 2 




8832/85 5 5 
10414/85 10 3 
17871/86 25 
9562/85 25 4 57 70 
13131/85 20 
6927/86 10 1 
17588/86 5 2 
8442/86 15 3 75.4 81.1 
16106/86 25 1 
12151/85i 15 
12151/85ii 15 
2415/87 5 2 
3482/86 70 
3296/87 15 1 
3716/86 10 3 
10395/86 15 4 
9558/85 15 1 
11717/85 15 1 59 45.8 
14515/85 10 2 
18243/86 15 0.5 
1222/86 15 1 
3235/86 15 2 82.5 90.5 
1709/86i 25 
1709/86ii 20 
14922/86 5 36.3 78.8 
4136/86 5 
4166/86 15 1 
1075/86 10 1 77.4 80.2 
2268/86R 20 85.4 72.2 
2268/86L 5 59.6 55.7 
188/86 60 5 
18005/85 5 2 60 76 
1319/86 5 3 
859/86 20 
12045/86 10 0.5 76.3 44.1 
1741/87 5 1 
12893/86 15 2 58.2 71. 4 
9912/86 15 
1145/87 10 3 
17530/86 10 
18246/86 5 1 
9200/86 5 
15875/85 15 2 
5194/86 25 4 69.2 70.8 
8163/86 5 1 
4806/86 15 0.5 
15213/85 15 1 38.8 34.6 
1980/87 10 3 
5543/86 5 1 
11297/85 15 1 
8855/86 5 
10286/86 10 2 91. 5 85.6 
6728/86 5 58.4 74.6 
14919/85 5 ,., 0 
14610/85 30 
17828/86 15 2 
16852/85 10 3 39 44.2 
14047/85 10 1 95.5 94.1 
17253/85 25 2 
5917/86i 10 
5917/86ii 15 
11063/85 20 3 
12896/86 5 2 
11918/86 5 1 
17021/85 10 1 
-17610/85 10 2 
16108/85 10 55.7 57.1 
